

**RECEIVED**  
AUG 19 2002  
TECH CENTER 1600/2900

GP 1642

**PATENT**

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Commissioner for Patents, Washington, D.C. 20231 on August 10, 2002.

Catherine M. Peck August 12, 2002  
Catherine M. Peck Date

P#4

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Serial No: 10/068,067  
Conf. No.: 7530  
Filed: February 5, 2002  
Applicants: Rothenberg et al.  
Title: **REGULATION OF CCR3 EXPRESSION**  
Art Unit: 1642  
Examiner: Not yet assigned  
Atty. Dkt.: CMC/153

Cincinnati, Ohio 45202

August 12, 2002

Commissioner for Patents  
Washington, D.C. 20231

Sir:

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**


In accordance with the duty of candor and good faith imposed by 37 CFR §1.56 and means of complying therewith according to 37 C.F.R. §§ 1.97 and 1.98, the references listed on the attached PTO-1449 are called to the attention of the United States Patent and Trademark Office in connection with the above-identified patent application.

Copies of the cited references are attached hereto. No representation is made that the cited art is the only art or that the cited art represents the best art. The Examiner is urged to consider the cited references and to make an independent decision with respect to their materiality.

Applicants know of no fee that is required with this submission.  
However, should any fees be deemed necessary herein, the Commissioner is hereby  
authorized to charge any such fees to Deposit Account No. 23-3000.

Respectfully submitted,

WOOD, HERRON & EVANS, L.L.P.

  
Beverly A. Lyman  
Reg. No. 41,961

2700 Carew Tower  
441 Vine Street  
Cincinnati, OH 45202  
(513) 241-2324  
(513) 421-7269 Facsimile

SUBSTITUTE FORM PTO-1449  
(MODIFIED)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
CMC/153SERIAL NO.  
10/O68,067INFORMATION DISCLOSURE  
STATEMENT BY APPLICANTAPPLICANT  
Marc E. Rothenberg et al.

(37 CFR 1.98(b))

(Use several sheets if necessary)

FILING DATE  
February 5, 2002GROUP  
1642

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A.A						
	A.B						
	A.C						
	A.D						
	A.E						
	A.F						
	A.G						
	A.H						
	A.I						
	A.J						
	A.K						

## FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

	DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	A.L					
	A.M					
	A.N					
	A.O					
	A.P					
	A.Q					

## OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

A.R	Barker, et al., <u>Cloning and Sequence Analysis of the Human Gene Encoding Eosinophil Major Basic Protein</u> , Gene, 1990, 86, 285
A.S	Daugherty, Bruce L., <u>The <math>\beta</math>-Chemokine Receptor Genes CCR1 (CMKBR1), CCR2 (CMKBR2), and CCR3 (CMKBR3) Cluster within 285 kb on Human Chromosome 3p21</u> , Genomics 41, 294-295 (1997)
A.T	Foster, et al., <u>Elemental Signals Regulating Eosinophil Accumulation in the Lung</u> , Immunological Reviews 2001, Vol. 179: 173-181

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449  
(MODIFIED)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
CMC/153SERIAL NO.  
10/O68,067INFORMATION DISCLOSURE  
STATEMENT BY APPLICANTAPPLICANT  
Marc E. Rothenberg et al.

(37 CFR 1.98(b))

(Use several sheets if necessary)

FILING DATE  
February 5, 2002GROUP  
1642

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	B.A						
	B.B						
	B.C						
	B.D						
	B.E						
	B.F						
	B.G						
	B.H						
	B.I						
	B.J						
	B.K						

## FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

	DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	B.L					
	B.M					
	B.N					
	B.O					
	B.P					
	B.Q					

## OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

B.R	Gomolin, et al., <u>Human Eosinophil Charcot-Leyden Crystal Protein: Cloning and Characterization of a Lysophospholipase Gene Promoter</u> , Blood, Vol. 82, No. 6, September 15, 1993, 1868-1874
B.S	Kavanaugh, et al., <u>Analysis of the CCR3 Promoter Reveals Cell-Specific Regulatory Regions Including Gata-1 Sites in Untranslated Exon 1</u> , J Allergy Clin Immunol, Abstracts, February 2001, S224
B.T	Leckie, et al., <u>Effects of an Interleukin-5 Blocking Monoclonal Antibody on Eosinophils, Airway Hyper-responsiveness, and the Late Asthmatic Response</u> , The Lancet, Vol. 356, December 23, 2000, 2144

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449  
(MODIFIED)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
CMC/153SERIAL NO.  
10/O68,067INFORMATION DISCLOSURE  
STATEMENT BY APPLICANTAPPLICANT  
Marc E. Rothenberg et al.

(37 CFR 1.98(b))

(Use several sheets if necessary)

FILING DATE  
February 5, 2002GROUP  
1642

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	C.A						
	C.B						
	C.C						
	C.D						
	C.E						
	C.F						
	C.G						
	C.H						
	C.I						
	C.J						
	C.K						

## FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

	DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	C.L					
	C.M					
	C.N					
	C.O					
	C.P					
	C.Q					

## OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

C.R	Mack, et al., <u>Aminooxypentane-RANTES Induces CCR5 Internalization but Inhibits Recycling: A Novel Inhibitory Mechanism of HIV Infectivity</u> , Journal of Exp. Med., 198. 1215, April 20, 1998
C.S	McDermott, et al., <u>CCR5 Promoter Polymorphism and HIV-1 Disease Progression</u> , The Lancet, Vol. 351, September 12, 1998
C.T	Moriuchi, et al., <u>Cloning and Analysis of the Promoter Region of CCR5, a Coreceptor for HIV-1 Entry</u> , Journal of Immunology, Vol. 159, 5441, 1997

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Substitute Disclosure Form (PTO-1449)

SUBSTITUTE FORM PTO-1449  
(MODIFIED)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
CMC/153SERIAL NO.  
10/O68,067INFORMATION DISCLOSURE  
STATEMENT BY APPLICANTAPPLICANT  
Marc E. Rothenberg et al.

(37 CFR 1.98(b))

(Use several sheets if necessary)

FILING DATE  
February 5, 2002GROUP  
1642

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	D.A						
	D.B						
	D.C						
	D.D						
	D.E						
	D.F						
	D.G						
	D.H						
	D.I						
	D.J						
	D.K						

## FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	D.L						
	D.M						
	D.N						
	D.O						
	D.P						
	D.Q						

## OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

D.R	Sun, et al., <u>Identification and Characterization of a Functional Promoter Region in the Human Eosinophil IL-5 Receptor <math>\alpha</math> Subunit Gene</u> , The Journal of Biological Chemistry, Vol. 270, No. 3, January 20, 1995, 1462-1471
D.S	Webb, et al., <u>Distinct Spatial Requirement for Eosinophil-induced Airways Hyperactivity</u> , Immunology and Cell Biology (2001) 79, 165-169
D.T	Yamaguchi, et al., <u>Functional Characterization of the Promoter for the Gene Encoding Human Eosinophil Peroxidase</u> , The Journal of Biological Chemistry, Vol. 269, No. 30, July 29, 1994, 19410

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449  
(MODIFIED)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
CMC/153SERIAL NO.  
10/O68,067INFORMATION DISCLOSURE  
STATEMENT BY APPLICANTAPPLICANT  
Marc E. Rothenberg et al.

(Use several sheets if necessary)

FILING DATE  
February 5, 2002GROUP  
1642

(37 CFR 1.98(b))

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
E.A.							
E.B.							
E.C.							
E.D.							
E.E.							
E.F.							
E.G.							
E.H.							
E.I.							
E.J.							
E.K.							

## FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
E.L.							
E.M.							
E.N.							
E.O.							
E.P.							
E.Q.							

## OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

E.R.	Yamamoto, et al., <u>Cloning and Functional Characterization of the 5'-Flanking Region of the Human Monocyte Chemoattractant Protein-1 Receptor (CCR2) Gene</u> , The Journal of Biological Chemistry, Vol. 274, No. 8, February 19, 1999, P. 4646
E.S.	Zimmermann, et al., <u>CC Chemokine Receptor-3 Undergoes Prolonged Ligand-induced Internalization*</u> , The Journal of Biological Chemistry, Vol. 274, No. 18, April 30, 1999, pp. 12611-12618
E.T.	Zimmermann, et al., <u>Molecular Analysis of CCR-3 Events in Eosinophilic Cells</u> , The Journal of Immunology, 2000, 164, 1055

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.